Guru P. Sonpavde, MD

Articles

New Strategies Enhance Care in mUC

November 25th 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma

August 14th 2020

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer

November 2nd 2019

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Sonpavde on Neoadjuvant Immunotherapy in Bladder Cancer

October 26th 2019

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

October 9th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Dr. Sonpavde on Emerging Immunotherapy Approaches in Bladder Cancer

July 24th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses emerging immunotherapy approaches in bladder cancer.

Dr. Sonpavde on the Biggest Challenges in Bladder Cancer

July 17th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.

Dr. Sonpavde on Agents Under Investigation in PD-L1-Low Bladder Cancer

June 5th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

x